Cancer Research Technology
Log in Register
Menu

pJEK5 Alpha-Synuclein A53T Vector

Invented by Dr Fiona Benson from Lancaster University
Invented at Lancaster University

Info

Catalogue Number 152048
Relevance Alpha synuclein is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.

A point mutation in the α-synuclein gene, A53T (Ala53-Thr), is linked to familial Parkinson′s disease. Mice expressing A53T human α-synuclein, but not wild-type or the A30P variants, develop adult-onset neurodegenerative disease with a progressive motoric dysfunction leading to death
Research Area Neurobiology
Notes pJEK5 ("A53T") is a derivative of pET15b with the open reading frame encoding the A53T mutant human α-synuclein cloned in via the NdeI and BamHI restriction sites. It was constructed via site-specific mutagenesis of pJEK1, replacing the G at position 88 in the ORF nucleotide sequence with a C, thus altering the 30th codon from GCA encoding Ala, to CCA encoding Pro. In this construct A30P alpha-synuclein is expressed as a fusion protein with an N-terminal six His tag.

References

There are 0 reference entries for this reagent.

References: 0 entry

There is no reference for this reagent yet, feel free to use the button below to suggest one.

Add a reference

References: 0 entry

There is no reference for this reagent yet, feel free to use the button below to suggest one.

Add a reference